Mollenhauer, Brit

Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium

McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 4,476

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders

Dementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and Treatments

Cited by 2,609

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Cantuti-Castelvetri, L., Ojha, R., Pedro, L. D., Djannatian, M., Franz, J., Kuivanen, S., van der Meer, F., Kallio, K., Kaya, T., Anastasina, M., et al. (2020) · Science

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,925

CSF and blood biomarkers for Parkinson's disease

Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., & Calabresi, P. (2019) · The Lancet Neurology

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 673

The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder

Heintz‐Buschart, A., Pandey, U., Wicke, T., Sixel‐Döring, F., Janzen, A., Sittig‐Wiegand, E., Trenkwalder, C., Oertel, W. H., Mollenhauer, B., & Wilmes, P. (2018) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsGut microbiota and health

Cited by 554

A practical guide to immunoassay method validation

Andreasson, U., Perret-Liaudet, A., van Waalwijk van Doorn, L. J. C., Blennow, K., Chiasserini, D., Engelborghs, S., Fladby, T., Genc, S., Kruse, N., Kuiperij, H. B., et al. (2015) · Frontiers in Neurology

Clinical Laboratory Practices and Quality ControlAdvanced Biosensing Techniques and Applications

Cited by 546

Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies

Stuendl, A., Kunadt, M., Kruse, N., Bartels, C., Moebius, W., Danzer, K. M., Mollenhauer, B., & Schneider, A. (2016) · Brain

Parkinson's Disease Mechanisms and TreatmentsExtracellular vesicles in disease

Cited by 428

Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 382

Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An Update

del Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine

Clinical Laboratory Practices and Quality ControlDementia and Cognitive Impairment Research

Cited by 343

Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype

Minakaki, G., Menges, S., Kittel, A., Emmanouilidou, E., Schaeffner, I., Barkovits, K., Bergmann, A., Rockenstein, E., Adame, A., Marxreiter, F., et al. (2018) · Autophagy

Parkinson's Disease Mechanisms and TreatmentsExtracellular vesicles in disease

Cited by 272

Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates

Arotcarena, M.-L., Dovero, S., Prigent, A., Bourdenx, M., Camus, S., Porras, G., Thiolat, M.-L., Tasselli, M., Aubert, P., Kruse, N., et al. (2020) · Brain

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 210

Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies

Poggiolini, I., Gupta, V., Lawton, M., Lee, S., El-Turabi, A., Querejeta-Coma, A., Trenkwalder, C., Sixel-Döring, F., Foubert-Samier, A., Pavy-Le Traon, A., et al. (2022) · Brain

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 191

Integrated Analyses of Microbiome and Longitudinal Metabolome Data Reveal Microbial-Host Interactions on Sulfur Metabolism in Parkinson’s Disease

Hertel, J., Harms, A. C., Heinken, A., Baldini, F., Thinnes, C. C., Glaab, E., Vasco, D. A., Pietzner, M., Stewart, I. D., Wareham, N. J., et al. (2019) · Cell Reports

Gut microbiota and healthParkinson's Disease Mechanisms and Treatments

Cited by 162

Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2009) · Journal of Neural Transmission

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 152

β-Synuclein-reactive T cells induce autoimmune CNS grey matter degeneration

Lodygin, D., Hermann, M., Schweingruber, N., Flügel-Koch, C., Watanabe, T., Schlosser, C., Merlini, A., Körner, H., Chang, H.-F., Fischer, H. J., et al. (2019) · Nature

Multiple Sclerosis Research StudiesNeuroinflammation and Neurodegeneration Mechanisms

Cited by 140

Biobanking of CSF: International standardization to optimize biomarker development

Teunissen, C. E., Tumani, H., Engelborghs, S., & Mollenhauer, B. (2014) · Clinical Biochemistry

Cerebrospinal fluid and hydrocephalusClinical Laboratory Practices and Quality Control

Cited by 137

Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease

Liu, G., Peng, J., Liao, Z., Locascio, J. J., Corvol, J.-C., Zhu, F., Dong, X., Maple-Grødem, J., Campbell, M. C., Elbaz, A., et al. (2021) · Nature Genetics

Parkinson's Disease Mechanisms and TreatmentsGenetic Associations and Epidemiology

Cited by 127

A combined miRNA-piRNA signature to detect Alzheimer’s disease

Jain, G., Stuendl, A., Rao, P., Berulava, T., Pena Centeno, T., Kaurani, L., Burkhardt, S., Delalle, I., Kornhuber, J., Hüll, M., et al. (2019) · Translational Psychiatry

Extracellular vesicles in diseaseDementia and Cognitive Impairment Research

Cited by 121

α‐Synuclein in Plasma‐Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease

Stuendl, A., Kraus, T., Chatterjee, M., Zapke, B., Sadowski, B., Moebius, W., Hobert, M. A., Deuschle, C., Brockmann, K., Maetzler, W., et al. (2021) · Movement Disorders

Extracellular vesicles in diseaseParkinson's Disease Mechanisms and Treatments

Cited by 108

One-step nanoscale expansion microscopy reveals individual protein shapes

Shaib, A. H., Chouaib, A. A., Chowdhury, R., Altendorf, J., Mihaylov, D., Zhang, C., Krah, D., Imani, V., Spencer, R. K. W., Georgiev, S. V., et al. (2025) · Nature Biotechnology

Advanced Fluorescence Microscopy TechniquesForce Microscopy Techniques and Applications

Cited by 104

Protein variability in cerebrospinal fluid and its possible implications for neurological protein biomarker research

Schilde, L. M., Kösters, S., Steinbach, S., Schork, K., Eisenacher, M., Galozzi, S., Turewicz, M., Barkovits, K., Mollenhauer, B., Marcus, K., et al. (2018) · PLOS ONE

Advanced Proteomics Techniques and ApplicationsClinical Laboratory Practices and Quality Control

Cited by 75

Parkinson’s progression markers initiative: a milestone-based strategy to monitor Parkinson’s disease progression

Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., Chahine, L. M., Mollenhauer, B., Foroud, T., Galasko, D., et al. (2023) · Journal of Parkinson’s Disease

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 70

A proteogenomic view of Parkinson’s disease causality and heterogeneity

Kaiser, S., Zhang, L., Mollenhauer, B., Jacob, J., Longerich, S., Del-Aguila, J., Marcus, J., Raghavan, N., Stone, D., Fagboyegun, O., et al. (2023) · npj Parkinson's Disease

Parkinson's Disease Mechanisms and TreatmentsAdvanced Proteomics Techniques and Applications

Cited by 68

CSF-derived extracellular vesicles from patients with Parkinson’s disease induce symptoms and pathology

Herman, S., Djaldetti, R., Mollenhauer, B., & Offen, D. (2023) · Brain

Parkinson's Disease Mechanisms and TreatmentsExtracellular vesicles in disease

Cited by 62